How Can We Help You?
There may be options to help you afford your Genentech medicine, no
matter what type of health insurance you have.
If you need help with the co-pay for your Genentech medicine, ZELBORAF Access Solutions can refer you to an independent co-pay assistance foundation.
An independent co-pay assistance foundation is a charitable
organization that gives financial assistance for medicines.
Call ZELBORAF Access Solutions at (888) 249-4918 for a referral.
If you would like to contact a foundation directly, you can use the information below:
No funds are available at this time.
Please call ZELBORAF Access Solutions at (888) 249-4918. We may be able to help.
Independent co-pay assistance foundations have their own rules for
eligibility. We cannot guarantee a foundation will help you. We only
can refer you to a foundation that supports your disease state. This
information is provided as a resource for you. We do not endorse or
show financial preference for any particular foundation. The
foundations in this list are not the only ones that might be able to
The Genentech® Access to Care Foundation is now the Genentech Patient Foundation.
We are still focused on giving free medicines to patients in need, but we've made some changes to provide better support to more patients, more quickly.
The Genentech Patient Foundation provides free medicines to
- Who don't have insurance
- Whose treatment is not covered by insurance
are struggling with high out-of-pocket costs
To learn more and to apply for help, visit GenentechPatientFoundation.com.
If you have health insurance coverage for your medicine, you must have already tried other types of patient assistance to qualify for free Genentech medicine from the Genentech Patient Foundation. This includes the ZELBORAF Co-pay Card Program and support from independent co-pay assistance foundations. You must also meet financial criteria. If you do not have insurance or your insurance does not cover your medicine, you must meet different financial criteria.
ZELBORAF Access Solutions can refer you to the Genentech BioOncology Co-pay Card. It can help you with the out-of-pocket costs for your Genentech medicine, if you’re eligible.
The Genentech BioOncology Co-pay Card helps patients with commercial
health insurance. This might be a plan you get through your employer
or one you purchased through a Health Insurance Marketplace like
HealthCare.gov. To qualify, you must also meet other criteria.
In order to be eligible for the Genentech BioOncology Co-pay Card,
the patient must have commercial insurance, must not have Medicare,
Medicaid or other government insurance, and must meet other
eligibility criteria. They also must agree to the rules set forth in
the terms and conditions for the program. Please visit CopayAssistanceNow.com for the full list of
terms and conditions.
How to Work With ZELBORAF Access Solutions
PAN=Patient Authorization and Notice of Request
for Transmission of Health Information to Genentech Access Solutions
and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
What it Treats
What is ZELBORAF APPROVED FOR?
ZELBORAF is a prescription medicine used to treat a type of skin cancer called melanoma that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal “BRAF” gene.
ZELBORAF is not used to treat melanoma with a normal BRAF gene.
Your healthcare provider will perform a test to make sure ZELBORAF is right for you.
ZELBORAF is a prescription medicine used to treat a type of blood cell cancer called Erdheim–Chester disease (ECD), that can affect body tissues and organs, and that has a certain type of abnormal “BRAF” gene.
It is not known if ZELBORAF is safe and effective in children under 18 years of age.
Important Safety Information
What is the most important information I should know about ZELBORAF?
ZELBORAF can cause serious side effects, including:
- Risk of new cancers. ZELBORAF may cause certain types of skin cancer called cutaneous squamous cell carcinoma (cuSCC) and keratoacanthoma. New melanoma lesions have occurred in people who take ZELBORAF. ZELBORAF may also cause another type of cancer called non-cutaneous squamous cell carcinoma (non-cuSCC). Talk with your healthcare provider about your risk for these cancers.
Check your skin and tell your healthcare provider right away about any skin changes, including:
- A new wart
- A skin sore or reddish bump that bleeds or does not heal
- A change in size or color of a mole
Your healthcare provider should check your skin before you start taking ZELBORAF, and every 2 months during treatment with ZELBORAF, to look for any new skin cancers. Your healthcare provider may continue to check your skin for 6 months after you stop taking ZELBORAF.
Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that you get while taking ZELBORAF.
Other blood cancers have happened in some people with Erdheim-Chester Disease (ECD) including those who take ZELBORAF. If you have other blood cancers and take ZELBORAF for ECD, your healthcare provider will monitor your blood cancer through routine blood tests.
Before you take ZELBORAF, tell your healthcare provider about all of your medical conditions, including if you:
- Have any heart problems, including a condition called long QT syndrome
- Have liver or kidney problems
- Have had or are planning to receive radiation therapy
- Have been told that you have low blood levels of potassium, calcium, or magnesium
- Are pregnant or plan to become pregnant. ZELBORAF can harm your unborn baby.
- Females who are able to become pregnant should use effective birth control during treatment with ZELBORAF and for 2 weeks after the final dose of ZELBORAF
- Talk to your healthcare provider about birth control methods that may be right for you
- Tell your healthcare provider right away if you become pregnant during treatment with ZELBORAF
- Are breastfeeding or plan to breastfeed. It is not known if ZELBORAF passes into your breast milk. Do not breastfeed during treatment with ZELBORAF and for 2 weeks after the final dose of ZELBORAF. Talk to your healthcare provider about the best way to feed your baby during this time.
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What should I avoid while taking ZELBORAF?
Avoid sunlight during treatment with ZELBORAF. ZELBORAF can make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. To help protect against sunburn:
- When you go outside, wear clothes that protect your skin, including your head, face, hands, arms, and legs.
- Use lip balm and a broad-spectrum sunscreen with SPF 30 or higher.
What are the possible side effects of ZELBORAF?
- Allergic reactions can happen while taking your ZELBORAF, and can be severe. Stop taking ZELBORAF and get medical help right away if you get any of these symptoms of an allergic reaction:
- Rash or redness all over your body
- Trouble breathing or swallowing
- Swelling of the face, lips, or tongue
- Throat tightness or hoarseness
- Feel faint
- Fast heartbeat
- Severe skin reactions. Stop taking ZELBORAF and call your healthcare provider right away if you get a skin rash with any of the following symptoms, because you may have a severe skin reaction:
- Blisters on your skin
- Blisters or sores in your mouth
- Peeling of your skin
- Redness or swelling of your face, hands, or soles of your feet
- Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider should do tests before you start taking ZELBORAF and during your treatment with ZELBORAF to check the electrical activity of your heart and your and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast while taking ZELBORAF. These may be symptoms related to QT prolongation.
- Liver injury. Your healthcare provider should do blood tests to check your liver function before you start taking ZELBORAF and during treatment. Tell your healthcare provider right away if you get any of these symptoms of a liver problem during treatment:
- Yellowing of your skin or the white part of your eyes
- Dark or brown (tea color) urine
- Nausea or vomiting
- Loss of appetite
- Pain on the right side of your stomach
- Eye problems. Tell your healthcare provider right away if you get any of these symptoms during treatment with ZELBORAF:
- Eye pain, swelling, or redness
- Blurred vision or other vision changes
- Worsening side effects from radiation treatment that can sometimes be severe or lead to death. Tell your healthcare provider if you have had or are planning to receive radiation therapy.
- Kidney injury. Your healthcare provider should do blood tests to check your kidney function before you start taking ZELBORAF and during treatment.
- Connective tissue disorders. Tell your healthcare provider if you develop an unusual thickening of the palms of your hands along with tightening of the fingers inward or any unusual thickening of the soles of your feet which may be painful.
The most common side effects of ZELBORAF in melanoma include:
- Joint pain
- Rash (see “Severe skin reactions” above)
- Hair loss
- Sunburn or sun sensitivity
The most common side effects of ZELBORAF in Erdheim-Chester Disease include:
- Joint pain
- Hair loss
- QT prolongation (see “Changes in the electrical activity of your heart called QT prolongation” above)
These are not all of the possible side effects of ZELBORAF. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see accompanying Full Prescribing Information and Medication Guide for additional Important Safety Information.